EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response

Milaid Granadillo, Alain B. Alfonso, Maribel G. Vallespi, Aileen Batte, Yordanka Soria, Enma Brown, Miladys Limonta, Yayrí C. Prieto, Laura Varas, Isis Torrens

Journal of Cellular Immunotherapy · 2016

DOI: 10.1016/j.jocit.2015.01.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Immunotherapy, 2016. Verfasst von Milaid Granadillo und 9 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Center for Genetic Engineering and Biotechnology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is common knowledge that these adjuvants predominantly induce humoral immunity, but some reports also describe their role combined with IL-12 in the induction of a Th1 immune response. In this study we want to investigate if alum could be an adjuvant to be used as a component of a therapeutic vaccine that require the generation of cell-mediated immunity. To demonstrate this concept we selected the human papillomavirus (HPV) 16-transformed mouse TC-1 cells as model and the fusion protein LALF32-51-E7 as antigen. Our results suggest that LALF32-51-E7 combined with aluminum hydroxide adjuvant promotes a Th1 immune response and consequently an anti-tumor response in the TC-1 tumor model. These results could have important application in future clinical trials in women with low grade squamous intraepithelial neoplasia.

Förderung

  • the Center for Genetic Engineering and Biotechnology

Zitieren

APA

Granadillo, M., Alfonso, A. B., Vallespi, M. G., Batte, A., Soria, Y., Brown, E., Limonta, M., Prieto, Y. C., Varas, L., & Torrens, I. (2016). The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response. Journal of Cellular Immunotherapy. https://doi.org/10.1016/j.jocit.2015.01.001

Vancouver

Granadillo M, Alfonso AB, Vallespi MG, Batte A, Soria Y, Brown E, et al. The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response. Journal of Cellular Immunotherapy. 2016. doi:10.1016/j.jocit.2015.01.001

BibTeX
@article{Granadillo2016,
  author = {Granadillo, Milaid and Alfonso, Alain B. and Vallespi, Maribel G. and Batte, Aileen and Soria, Yordanka and Brown, Enma and Limonta, Miladys and Prieto, Yayrí C. and Varas, Laura and Torrens, Isis},
  title = {The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response},
  journal = {Journal of Cellular Immunotherapy},
  year = {2016},
  doi = {10.1016/j.jocit.2015.01.001}
}
Kostenlos starten →